Ligands of Therapeutic Utility for the Liver X Receptors

被引:78
|
作者
Komati, Rajesh
Spadoni, Dominick
Zheng, Shilong
Sridhar, Jayalakshmi
Riley, Kevin E.
Wang, Guangdi [1 ]
机构
[1] Xavier Univ Louisiana, Dept Chem, New Orleans, LA 70125 USA
来源
MOLECULES | 2017年 / 22卷 / 01期
基金
美国国家卫生研究院;
关键词
liver X receptors; LXR; LXR specific ligands; atherosclerosis; diabetes; Alzheimer's disease; cancer; lipid metabolism; molecular modeling; interaction energy; REVERSE CHOLESTEROL TRANSPORT; PROSTATE-CANCER CELLS; NUCLEAR RECEPTOR; LXR-ALPHA; LIPID-METABOLISM; NATURAL-PRODUCT; TRANSCRIPTIONAL REGULATION; ANTIINFLAMMATORY ACTIVITY; HEPATIC LIPOGENESIS; OXYSTEROL RECEPTOR;
D O I
10.3390/molecules22010088
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Liver X receptors (LXRs) have been increasingly recognized as a potential therapeutic target to treat pathological conditions ranging from vascular and metabolic diseases, neurological degeneration, to cancers that are driven by lipid metabolism. Amidst intensifying efforts to discover ligands that act through LXRs to achieve the sought-after pharmacological outcomes, several lead compounds are already being tested in clinical trials for a variety of disease interventions. While more potent and selective LXR ligands continue to emerge from screening of small molecule libraries, rational design, and empirical medicinal chemistry approaches, challenges remain in minimizing undesirable effects of LXR activation on lipid metabolism. This review provides a summary of known endogenous, naturally occurring, and synthetic ligands. The review also offers considerations from a molecular modeling perspective with which to design more specific LXR ligands based on the interaction energies of ligands and the important amino acid residues in the LXR ligand binding domain.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] The emerging roles of liver X receptors and their ligands in cancer
    Lin, Chin-Yo
    Vedin, Lise-Lotte
    Steffensen, Knut R.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (01) : 61 - 71
  • [2] Liver X Receptors as potential therapeutic targets in atherosclerosis
    Zhu, Yanfei
    Li, Yousheng
    CLINICAL AND INVESTIGATIVE MEDICINE, 2009, 32 (05): : E383 - E394
  • [3] Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia
    Beltowski, Jerzy
    CARDIOVASCULAR THERAPEUTICS, 2008, 26 (04) : 297 - 316
  • [4] Liver X Receptors as Therapeutic Targets in Metabolism and Atherosclerosis
    Nomiyama, Takashi
    Bruemmer, Dennis
    CURRENT ATHEROSCLEROSIS REPORTS, 2008, 10 (01) : 88 - 95
  • [5] Liver X receptors as therapeutic targets in metabolism and atherosclerosis
    Takashi Nomiyama
    Dennis Bruemmer
    Current Atherosclerosis Reports, 2008, 10 : 88 - 95
  • [6] Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors
    Ondeyka, JG
    Jayasuriya, H
    Herath, KB
    Guan, ZQ
    Schulman, M
    Collado, J
    Dombrowski, AW
    Kwon, SS
    McCallum, C
    Sharma, N
    MacNaul, K
    Hayes, N
    Menke, JG
    Singh, SB
    JOURNAL OF ANTIBIOTICS, 2005, 58 (09): : 559 - 565
  • [7] Steroidal and Triterpenoidal Fungal Metabolites as Ligands of Liver X Receptors
    John G Ondeyka
    Hiranthi Jayasuriya
    Kithsiri B Herath
    Ziqiang Guan
    Marvin Schulman
    Javier Collado
    Anne W Dombrowski
    Soojin S Kwon
    Christine McCallum
    Neelam Sharma
    Karen MacNaul
    Nancy Hayes
    John G Menke
    Sheo B Singh
    The Journal of Antibiotics, 2005, 58 : 559 - 565
  • [8] Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease
    Fitz, Nicholas F.
    Nam, Kyong Nyon
    Koldamova, Radosveta
    Lefterov, Iliya
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (18) : 3599 - 3610
  • [9] Therapeutic modulation of retinoid X receptors - SAR and therapeutic potential of RXR ligands and recent patents
    Schierle, Simone
    Merk, Daniel
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2019, 29 (08) : 605 - 621
  • [10] Liver X receptors as potential therapeutic targets for multiple diseases
    Cao, GQ
    Liang, Y
    Jiang, XC
    Eacho, PI
    DRUG NEWS & PERSPECTIVES, 2004, 17 (01) : 35 - 41